KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Other Accumulated Expenses: 2009-2018

Historic Other Accumulated Expenses for Alnylam Pharmaceuticals (ALNY) over the last 6 years, with Dec 2018 value amounting to $23.6 million.

  • Alnylam Pharmaceuticals' Other Accumulated Expenses rose 117.66% to $23.6 million in Q4 2018 from the same period last year, while for Dec 2018 it was $23.6 million, marking a year-over-year increase of 117.66%. This contributed to the annual value of $23.6 million for FY2018, which is 117.66% up from last year.
  • According to the latest figures from FY2018, Alnylam Pharmaceuticals' Other Accumulated Expenses is $23.6 million, which was up 117.66% from $10.9 million recorded in FY2017.
  • In the past 5 years, Alnylam Pharmaceuticals' Other Accumulated Expenses registered a high of $23.6 million during FY2018, and its lowest value of $3.8 million during FY2014.
  • Moreover, its 2-year median value for Other Accumulated Expenses was $17.2 million (2017), whereas its average is $17.2 million.
  • Data for Alnylam Pharmaceuticals' Other Accumulated Expenses shows a peak YoY surged of 117.66% (in 2018) over the last 5 years.
  • Over the past 4 years, Alnylam Pharmaceuticals' Other Accumulated Expenses (Yearly) stood at $3.8 million in 2014, then surged by 30.38% to $5.0 million in 2015, then reached $10.9 million in 2017, then surged by 117.66% to $23.6 million in 2018.